Head-to-head clinical trials evaluating more than 1600 patients

RMS OPERA I and II study design 4,6

The efficacy and safety of OCREVUS (ocrelizumab) in RMS were studied vs Rebif in 2 double-blind, double-dummy trials evaluating more than 1600 patients for 2 years.

MRI and clinical results vs Rebif

5 key clinical efficacy endpoints 4,6

OCREVUS demonstrated superior clinical results vs Rebif across 5 key endpoints over 2 years.

More than 6 years of safety data

OCREVUS safety profile for RMS 2-4

The safety of OCREVUS for RMS was studied in the 2-year controlled OPERA I and II clinical trials and observed in over 4 years of open-label extension study.

RMS=relapsing multiple sclerosis.